Pharmacokinetics of Tedizolid in Subjects with Renal or Hepatic Impairment

Two open-label, single-dose, parallel-group studies were conducted to characterize the pharmacokinetics of the novel antibacterial tedizolid and the safety of tedizolid phosphate, its prodrug, in renally or hepatically impaired subjects. Tedizolid pharmacokinetics in subjects with severe renal impai...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Antimicrob Agents Chemother
Glavni autori: Flanagan, S., Minassian, S. L., Morris, D., Ponnuraj, R., Marbury, T. C., Alcorn, H. W., Fang, E., Prokocimer, P.
Format: Artigo
Jezik:Inglês
Izdano: American Society for Microbiology 2014
Teme:
Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4249404/
https://ncbi.nlm.nih.gov/pubmed/25136024
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03431-14
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items